http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100430141-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-10 |
| filingDate | 2000-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100430141-B1 |
| titleOfInvention | Osthenol derivatives and composition for preventing or treating prostate disease comprising same |
| abstract | The present invention relates to an austenol derivative of Formula 1 and a pharmacologically acceptable salt thereof, and a composition for preventing or treating prostate disease.n n n n n n n n n n Wheren n n R 1 is hydrogen; Unsubstituted or mono or polysubstituted (C 1 -C 5 ) alkyl, (C 2 -C 6 ) alkenyl or (C 2 -C 6 ) alkynyl; (C 1 -C 7 ) alkylcarbonyl; benzyl; Or (C 3 -C 7 ) allylcarbonyl or (C 3 -C 7 ) allylcarbamyl,n n n R 2 is hydroxy or (C 2 -C 5 ) alkyl or (C 2 -C 6 ) alkenyl substituted with (C 1 -C 5 ) alkyl-OCO-; orn n n OR 1 and R 2 together may form an unsubstituted or substituted oxygen containing 5 or 6 membered hetero ring. |
| priorityDate | 2000-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.